May 26, 2017 8:21am

 

Investors will shudder, but they will adjust as they always do.

 

I have a messages from the past “keep your helmet on and stay away from walls”

 

As related to being long over a holiday weekend with politics boiling over …

 

Lower open expected

Companies in my headlights:  eleven (11), 5 BUYS and 6 SELLS

.

Critical information ahead of “our” universe’s open! I provide intelligence and analysis for short and near-term investment.

You could be reading this ... IF you were a subscriber ...

 

 

 


 

Expectation is the word for 2017 – meeting the unknowns with the soon to be exposed concerns will be the subject of investing decisions throughout this year.

 

 

Dow futures are DOWN -0.20% and NASDAQ futures are DOWN -0.16%

 

U.S. stock index futures pointed to a slightly lower open on Friday as traders appeared to move away from riskier assets amid fluctuating oil prices.

European markets were mixed as slumping oil prices continued to weigh on investor sentiment.

Asia markets finished mostly lower, despite an agreement from major oil producers at an OPEC meeting to extend output cuts for an additional nine months.

 

Data docket: durable goods orders for April released at around 8:30 a.m. ET. Revised gross domestic product (GDP) data for the first-quarter of 2017 and revised consumer sentiment data for May are both scheduled to be posted before 10 a.m. ET.

 

 

The cell therapy sector closed NEGATIVE on Thursday, Wednesday, POSITIVE on Tuesday, NEGATIVE on Monday and POSITIVE last Friday.

The cell therapy sector’s record after the last 5 days (of 43 covered companies):

·         Thursday closed NEGATIVE with 24 decliners, 17 advancers and 2 flats;

·         Wednesday closed NEGATIVE with 21 decliners, 16 advancers and 6 flats;

·         Tuesday closed POSITIVE with 15 decliners, 25 advancers and 3 flats;

·         Monday closed NEGATIVE with 21 decliners, 19 advancers and 3 flats;

·         Last Friday closed POSITIVE with 15 decliners, 26 advancers and 2 flat;

 

 

Remembering Thursday’s closing bell newsletter, “sector selling kept coming.”

Reiterating, “Worry about losing money, not making money. Cut out those with heavy losses and the winners will take care of themselves!”

 

​I just can't wait for this week to be O V E R !

 

 

What did I see on Thursday, the DOW closing UP +0.34% (+70.53) as the NASDAQ also closed UP +0.69% (+42.23) … the CBOE Volatility Index (VIX) widely considered the best gauge of fear in the market, traded near 9.4 …

 

The count - gainers: look at the differences in the spreads and advance/decline lines – look at how the numbers define volatility:

·         Thursday’s decliners ranged from -0.55% <CLLS> to -8.46% <MESO> in 24 equities;

·         Wednesday’s decliners ranged from -0.03% <OPXA> to -4.46% <CAPR> in 21 equities;

·         Tuesday’s decliners ranged from -0.24% <BCLI> to -8.54% <ISCO> in 15 equities;

·         Monday’s decliners ranged from -0.45% <BLFS> to -21.67% <BSTG> in 21 equities;

·         Friday’s decliners ranged from -0.17% <BSTG> to -6.78% <BLUE> in 15 equities;

While gainers…

·         Thursday’s gainers ranged from +0.06% <BLUE> to +4.79% <CAPR> in 17 equities;

·         Wednesday’s gainers ranged from +0.16% <ONCE> to +8.46% <NWBO> in 16 equities;

·         Tuesday’s gainers ranged from +0.51% <OSIR> to +13.62% <BSTG> in 25 equities;

·         Monday’s gainers ranged from +0.28% <RGNX> to +12.77% <OPXA> in 19 equities;

·         Friday’s gainers ranged from +0.01% <HSGX> to +10.66% <QURE> in 26 equities;

 

 

You’ve made it to the office, turned on the monitor, having just gotten your coffee and it hits you - what could be today’s trades? 

Watch list:

  • The iShares Nasdaq Biotechnology (IBB) closed down -0.22% on Thursday, and is indicating a NEGATIVE -0.43% in Friday’s pre-market;
  • The SPDR S&P Biotech ETF (XBI) closed Thursday down -0.49% and is indicating a NEGATIVE -0.02% in Friday pre-market;
  • The Health Care Select Sector SPDR ETF (XLV) closed up +0.48% Thursday, and is NOT indicating n Friday’s pre-open;
  • The iShares Russell 2000 (IWM) closed up +0.09% on Thursday, and is indicating a NEGATIVE -0.37% in Friday’s pre-open

 

 

Companies in my headlights – I am not lazy in defining any upside or downside, I just don’t see any input other than momentum.

 

The issue: there is NO news or impetus for many of these stocks other than pure speculation …

 

Applied Genetic Technologies (AGTC) closed up +$0.10 to $5.45 and  the aftermarket indication was a NEGATIVE -$0.025 or -0.46%  – SELL;

AxoGen (AXGN) closed up +$0.15 to $15.40. The aftermarket indication is a POSITIVE +$0.05 or +0.33% - BUY

Bellicum Pharmaceuticals (BLCM) closed down -$0.29 to $12.19. The aftermarket indication is a positive +$0.0827 or +0.68%. Oversold - BUY;

bluebird bio (BLUE) closed up +$0.05 to $79.80 following Wednesday’s $79.75 (-$0.60). The aftermarket indication is a NEGATIVE -$0.35 or -0.44% - BUY to SELL;

Capricor (CAPR) closed up +$0.04 to $0.83. The aftermarket indication is a POSITIVE +$0.0249 or +2.98% - BUY;

Juno Therapeutics (JUNO) closed UP +$0.19 to $25.52. The aftermarket indication is a POSITIVE +$0.45 or +1.76% - BUY;

Kite Pharma (KITE) closed up +$3.25 to $74.91. The aftermarket indication is a NEGATIVE -$0.01 or -0.01% - SELL;

Mesoblast (MESO) closed down $   the aftermarket indication was -$0.66 or -7.85% - SELL;

Organovo (ONVO) closed flat at $2.85. The aftermarket indication is a NEGATIVE -$0.02 or -0.69% - SELL;

Regenxbio (RGNX) closed down -$0.20 to $18.65 following Wednesday’s $18.85 (+$0.25). The aftermarket indication is a NEGATIVE -$0.125 or +0.06% - SELL;

Spark Therapeutics (ONCE) closed up +$0.33 to $55.62 following Wednesday’s $55.28 (+$0.08). The aftermarket indication is a POSITIVE +$0.32 or +0.58% - SELL to BUY;

 

 

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

Henry’s comments are for informational purposes only and are not a substitute for personalized advice. Consult your advisor about what is best for you.